ClinicalTrials.gg
RecruitingNCT06323564INTELLEGOUpdated Mar 21, 2024

Exploring Emotional Intelligence and Cognitive Flexibility in Anorexia Nervosa and Parkinson's Disease.

An observational study in Anorexia Nervosa and Parkinson Disease, sponsored by Istituto Auxologico Italiano. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-21.

Sponsored by Istituto Auxologico Italiano · Observational

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 18 studies in Anorexia Nervosa by Istituto Auxologico Italiano — 4 open to participants now, 4 under way, none of them phase 3. Anorexia Nervosa · Istituto Auxologico Italiano.

Planned enrollment
3rd of 15
80 · median 60
Started
2023
with 5 others
Observational
15 of 18
2 open now
Registered
9th of 18
by date

Among the 18 studies in Anorexia Nervosa by Istituto Auxologico Italiano, this one is the 3rd largest by planned enrollment of the 15 observational ones that give a count, is one of 6 that started in 2023, is one of 15 observational ones, and was the 9th registered.

Anorexia Nervosa

469 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

4 of the 18 studies in Anorexia Nervosa by Istituto Auxologico Italiano are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 83 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 61 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Anorexia Nervosa by Istituto Auxologico Italiano, or all of them as a file.
02

Study summary

The main aim of this study is to demonstrate how disorders characterized by different types of "inflexibility", cognitive-affective type for Anorexia nervosa and motor one for Parkinson's disease, have an impact on how emotional stimuli are processed and on the transition within emotional states.

Read the detailed description

Although many psychometric models have been developed on emotions, affect measurements, which represent the measurement of behavioural, subjective and neuropsychophysiological changes associated with an emotional episode, still remains one of the most debated topics. Emotions are entities with blurred boundaries and with substantial idiosyncrasies that characterize their measurable manifestations. One of the most consolidated theoretical reference models for measuring affect is that of James Russel called the "Affective Core Model". According to this model, emotion arises when the undifferentiated and pre-reflective magma of affect (core affect) is attracted by an external (or internal) object that can be defined as emotigenic, i.e. capable of defining the nature of emotional experience by orienting it along two dimensions principal factors. The most used theoretical model for affect measurement is the one that describes an emotional episode in the light of two distinguishable continuous dimensions: that of hedonic value (identifies the degree of pleasantness of the emotional event), of a subjective nature, and that of arousal or psychophysiological activation. Although this model has been widely corroborated in various disciplines, there is still a lack of a clear description of the process that allows an individual to transition from one emotionally object-oriented state to another.

This project proposes and intends to validate a new modality of three-dimensional psychometric modeling of emotions, based on the intersection between the consolidated two-dimensional model of arousal-valence and a third purely cognitive component definable as mental flexibility, capable of including high-level cognitive processes, intrinsically connected with the emotional sphere, such as emotional intelligence (Emotional Intelligence, EI) and emotional regulation.

03

Conditions studied

  • Anorexia Nervosa
  • Parkinson Disease

Keywords

  • Emotional intelligence
  • Cognition
  • Emotional valence
  • Anorexia nervosa
  • Parkinson's disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients affected by Parkinson's Disease and Anorexia Nervosa

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parkinson's Disease
  • Anorexia nervosa
  • Written

Exclusion criteria

Exclusion Criteria:

  • Other psychiatric disorders
  • Acute infectious diseases
  • Chronic inflammatory diseases
  • Other Disorders of central nervous system
  • Pregnancy or breastfeeding
  • tachy or bradyarrhythmias, other cardiac rhythm alterations that compromise the study of heart rate variability
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Parkinson Disease (PD)

    The trial will be divided into two periods T0 (first evaluation at the time of admission to hospital) and T1 (15 days after T0, during rehabilitation period in hospital for patients with Parkinson's disease). First, as soon as patients are admitted to acute care,neuropsychological tests and self-report questionnaires will be administered. Subsequently, at both T0 and T1, standardized emotional images from the International Affective Picture System (IAPS) will be administered. For the entire duration of the test, peripheral physiological parameters such as ECG, BVP, GSR, EOG, RSP and facial EMG (corrugator and zygomaticus) will also be detected, as objective measures of emotional arousal (T0-T1).

    Diagnostic Test: Neuropsychological tests in PD · Diagnostic Test: Self-report questionnaires in PD · Device: International Affective Picture System (IAPS)

  • Anorexia Nervosa (AN)

    The trial will be divided into two periods T0 (first evaluation at the time of admission to hospital) and T1 (4 weeks after T0, during rehabilitation period in hospital. First, as soon as patients are admitted to acute care, neuropsychological tests and self-report questionnaires will be administered. Subsequently, at both T0 and T1, standardized emotional images from the International Affective Picture System (IAPS) will be administered. For the entire duration of the test, peripheral physiological parameters such as ECG, BVP, GSR, EOG, RSP and facial EMG (corrugator and zygomaticus) will also be detected, as objective measures of emotional arousal (T0-T1). Furthermore, the analysis of bio-humoral parameters (interleukin 6, cortisol, serotonin, catecholamines and endorphins) will be also performed through morning venous blood sampling at T0, at half of the rehabilitation process and at T1.

    Device: International Affective Picture System (IAPS) · Diagnostic Test: Neuropsychological tests in AN · Diagnostic Test: Self-report questionnaires in AN · Diagnostic Test: Analysis of bio-humoral parameters

Interventions

  • Diagnostic testNeuropsychological tests in PD

    Colored Progressive Matrices (BDM), Stroop Test (Caffarra et al., 2000), Stroop Test (Caffarra et al., 2000), Attentional Matrices (part I - Della Sala et al., 1992), Attentional Matrices (part The - Della Sala et al., 1992), Trail Making Test (Giovagnoli et al., 1996 - part A), Trail Making Test (Giovagnoli et al., 1996 - part B), Trail Making Test (Giovagnoli et al., 1996 - B-A), MMSE (Grigoletto et al., 1999), Clock Drawing - PD (Caffarra et al., 2011), Digit Span Forward (Orsini et al., 1987), Digit Span Backward (Monaco et al. , 2012), 15 Rey Words - Immediate Recall (BDM), 15 Rey Words - Deferred Recall (BDM), Phonemic Fluency (Costa et al., 2014), Semantic Fluency (Costa et al., 2014), Frontal Assessment Battery ( FAB - Apollonio et al.,2005).

  • Diagnostic testSelf-report questionnaires in PD

    STAI Y2 (trait anxiety), TEIque (153 items), STAI Y1 (state anxiety), ERQ (10 items), EISR (33 items), BDI (21 items), WLEIS (16 ITEMS), CFI (20 ITEMS ), CCFQ (18 ITEM).

  • DeviceInternational Affective Picture System (IAPS)

    Subsequently, at both T0 and T1, standardized emotional images from the International Affective Picture System (IAPS) will be administered. The images will be chosen based on the arousal-valence parameters, eliminating those with stimuli that are too salient with respect to the disorders examined. The order of administration will be organized and randomized between subjects as follows: 24 blocks of 2 minutes and for each block there will be 12 images of 10 seconds each. For the entire duration of the test, peripheral physiological parameters such as ECG, BVP, GSR, EOG, RSP and facial EMG (corrugator and zygomaticus) will also be detected, as objective measures of emotional arousal (T0-T1).

  • Diagnostic testNeuropsychological tests in AN

    Verbal Fluencies, Tower of London, TMT-A \& B

  • Diagnostic testSelf-report questionnaires in AN

    STAI Y2 (20 items trait anxiety), TEIque (153 items), STAI Y1 (20 items state anxiety), DFlex (24 items), ERQ (10 items), EISR (33 items), BDI (21 items), TAS-20 (20 items), WLEIS (16 ITEMS), CFI (20 ITEMS), CCFQ (18 items).

  • Diagnostic testAnalysis of bio-humoral parameters

    the analysis of bio-humoral parameters (interleukin 6, cortisol, serotonin, catecholamines and endorphins) will be also performed through morning venous blood sampling at T0, at half of the rehabilitation process and at T1

06

What researchers measure

Primary outcomes

  1. Change in International Affective Picture System (IAPS)

    Self-Assessment Manikin (SAM) scale. Range score for each image: 1-5 (IAPS test: 24 blocks of 2 minutes and for each block there will be 12 images of 10 seconds each).

    Time frame: At baseline T0 (hospital admission) and T1 (15 days after T0 for PD, 4 weeks after T0 for AN)

Secondary outcomes

  1. Change in self-report questionnaires - STAI

    State-Trait Anxiety Inventory (STAI); score range 20-80

    Time frame: At baseline T0 (hospital admission) and T1 (15 days after T0 for PD, 4 weeks after T0 for AN)

  2. Change in self-report questionnaires - BDI

    Beck's Depression Inventory (BDI); score range 0-63

    Time frame: At baseline T0 (hospital admission) and T1 (15 days after T0 for PD, 4 weeks after T0 for AN)

  3. Change in Heart rate variability

    High frequency (range 0.15-0.40 hz) * Low frequency (range 00.4-0.15 hz) * Ratio Low frequency/High frequency

    Time frame: At baseline T0 (hospital admission) and T1 (15 days after T0 for PD, 4 weeks after T0 for AN)

  4. Change in analysis of bio-humoral parameters

    Serotonin in serum (range 30 - 200 ng/ml)

    Time frame: At baseline T0 (hospital admission), after 2 weeks and T1 (4 weeks after T0 for AN)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Aug 2024, 19 months after the start.

Of 56 non-industry observational studies under Anorexia Nervosa, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 72. This study's planned 19 months is below that.

Counting every sponsor, half of 56 studies reached it within 38 months; a quarter within 16 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2024
First posted
Mar 21, 2024
StartActual
Jan 13, 2023
Primary completionEst.
Aug 13, 2024
CompletionEst.
Jan 13, 2025
Last update
Mar 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06323564
Responsible party
Sponsor
First posted
Mar 21, 2024
Start date
Jan 13, 2023
Primary completion
Aug 13, 2024 (estimated)
Completion
Jan 13, 2025 (estimated)
Last update
Mar 21, 2024

Study contacts

Riccaro Cremascoli, MD, PhD
Contact
r.cremascoli@auxologico.it
+393497292068

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion